Two more product approvals in Russia for India's Claris
Claris Lifesciences (CLAR: IN), one of the largest sterile injectables pharmaceutical companies in India, has received approval from Russia’s Ministry of Health to market two more anti-infectives namely fluconazole IV 100 ml and levofloxacin IV 100 ml.
Fuconazole is a triazole antifungal drug used in the treatment and prevention of superficial and systemic fungal infections, where as levofloxacin is a synthetic anitbacterial agent of the fluoroquinolone class that is used to treat a broad range of infections.
Russia is one of the largest and fastest expanding pharmaceutical markets in the world, estimated to grow at 12%-15% compound annual growth rate (CAGR). The generic market size in Russia is estimated to be at $3.5 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze